Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT04447833
PHASE1

Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome

Sponsor: Uppsala University

View on ClinicalTrials.gov

Summary

This is an open label, dose escalating safety study of the advanced therapy investigational medicinal product (ATIMP) KI-MSC-PL-205, where patients diagnosed with SARS-CoV-2-induced severe acute respiratory distress syndrome (ARDS), according to the Berlin Definition, and who are on respirator/ventilator (used synonymously in this protocol) support due to respiratory insufficiency with or without concomitant circulatory problems, will be included and treated with a single dose of KI-MSC-PL-205.

Official title: Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome Validation of Mechanistic Pathways and Clinical Efficacy

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

7

Start Date

2020-06-17

Completion Date

2026-03-30

Last Updated

2025-04-25

Healthy Volunteers

No

Interventions

DRUG

Mesenchymal Stromal Stem Cells - KI-MSC-PL-205

Allogeneic bone marrow derived mesenchymal stromal stem cells (MSCs).

Locations (1)

Uppsala University Hospital

Uppsala, Sweden